Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Ipilimumab in Malignant Pleural Mesothelioma: NCT07563738 Clinical Landscape Report 2026
9 min read
Ipilimumab in Malignant Pleural Mesothelioma: NCT07563738 Clinical Landscape Report 2026
11 September 2026
NCT07563738 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Nintedanib esylate in Idiopathic Pulmonary Fibrosis: NCT07679893 Clinical Landscape Report 2026
9 min read
Nintedanib esylate in Idiopathic Pulmonary Fibrosis: NCT07679893 Clinical Landscape Report 2026
11 September 2026
NCT07679893 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Dexamethasone Sodium Phosphate in Uveal Melanoma: NCT07803562 Clinical Landscape Report 2026
9 min read
Dexamethasone Sodium Phosphate in Uveal Melanoma: NCT07803562 Clinical Landscape Report 2026
11 September 2026
NCT07803562 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Lenvatinib mesylate in Hepatocellular Carcinoma: NCT07801287 Clinical Landscape Report 2026
9 min read
Lenvatinib mesylate in Hepatocellular Carcinoma: NCT07801287 Clinical Landscape Report 2026
11 September 2026
NCT07801287 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Recombinant human coagulation factor VIII-Fc fusion protein (Gensciences) in Hemophilia A: NCT07663903 Clinical Landscape Report 2026
9 min read
Recombinant human coagulation factor VIII-Fc fusion protein (Gensciences) in Hemophilia A: NCT07663903 Clinical Landscape Report 2026
11 September 2026
NCT07663903 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Gemcitabine Hydrochloride in Diffuse large B-cell lymphoma recurrent: NCT07808827 Clinical Landscape Report 2026
9 min read
Gemcitabine Hydrochloride in Diffuse large B-cell lymphoma recurrent: NCT07808827 Clinical Landscape Report 2026
11 September 2026
NCT07808827 clinical landscape for Diffuse large B-cell lymphoma recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
Read →
Tislelizumab in Squamous cell carcinoma of the oral cavity: NCT07812467 Clinical Landscape Report 2026
9 min read
Tislelizumab in Squamous cell carcinoma of the oral cavity: NCT07812467 Clinical Landscape Report 2026
11 September 2026
NCT07812467 clinical landscape for Squamous cell carcinoma of the oral cavity: endpoints, sponsor, phase, geography, readouts, asset context and development…
Read →
ARR-002 in Metastatic endometrial cancer: NCT07755436 Clinical Landscape Report 2026
9 min read
ARR-002 in Metastatic endometrial cancer: NCT07755436 Clinical Landscape Report 2026
11 September 2026
NCT07755436 clinical landscape for Metastatic endometrial cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
BPR001 in Adenocarcinoma of large intestine: NCT07813884 Clinical Landscape Report 2026
9 min read
BPR001 in Adenocarcinoma of large intestine: NCT07813884 Clinical Landscape Report 2026
11 September 2026
NCT07813884 clinical landscape for Adenocarcinoma of large intestine: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
Read →
JSKN033 in Metastatic Carcinoma to the Uterine Cervix: NCT07797153 Clinical Landscape Report 2026
9 min read
JSKN033 in Metastatic Carcinoma to the Uterine Cervix: NCT07797153 Clinical Landscape Report 2026
11 September 2026
NCT07797153 clinical landscape for Metastatic Carcinoma to the Uterine Cervix: endpoints, sponsor, phase, geography, readouts, asset context and development…
Read →
Tilrekimig in Eczema: NCT07765888 Clinical Landscape Report 2026
9 min read
Tilrekimig in Eczema: NCT07765888 Clinical Landscape Report 2026
11 September 2026
NCT07765888 clinical landscape for Eczema: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Disitamab Vedotin in HER2 Positive Muscle Invasive Bladder Carcinoma: NCT07783815 Clinical Landscape Report 2026
9 min read
Disitamab Vedotin in HER2 Positive Muscle Invasive Bladder Carcinoma: NCT07783815 Clinical Landscape Report 2026
11 September 2026
NCT07783815 clinical landscape for HER2 Positive Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
Read →